SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

DISEASE CHARACTERISTICS: * Histologically\* confirmed Hodgkin's or non-Hodgkin's lymphoma (NHL) of any histology * The following NHL types are eligible: * Diffuse large B-cell lymphoma * Follicular lymphoma * Mantle Cell lymphoma * Marginal zone lymphoma (including lymphoma of mucosa-associated tissue \[MALT\]) * Anaplastic large cell lymphoma * Peripheral T-cell lymphoma * Cutaneous T-cell lymphoma * T/NK cell lymphoma * Angioimmunoblastic lymphadenopathy-type T-cell lymphoma * Burkitt's lymphoma NOTE: \* If histologic confirmation was made at initial diagnosis, confirmation of relapsed or refractory disease can be made by repeat histologic evaluation OR by evidence of regrowth at a site of disease that was previously histologically confirmed * Relapsed after or refractory to ≥ 2 prior therapeutic regimens OR patient is ineligible to receive potentially curative therapy * Bidimensionally measurable or evaluable (e.g., bone marrow or infiltrative organ involvement) disease by physical exam or radiographic study * No suspicion or evidence of lymphomatous meningitis PATIENT CHARACTERISTICS: * Life expectancy ≥ 12 weeks * ECOG performance status 0-4 * Not pregnant * Negative pregnancy test * Fertile patients must use medically prescribed contraception * Absolute neutrophil count ≥ 1,000/mm\^3\* * Platelet count ≥ 50,000/mm\^3\* * Hemoglobin ≥ 8 g/dL\* * Serum creatinine ≤ 2.0 mg/dL * Total bilirubin ≤ 2.0 mg/dL\*\* * Transaminases \< 5 times upper limit of normal\*\* * No other malignancy within the past 5 years other than curatively treated non-metastatic skin cancer or in situ cervical carcinoma * No history of significant or symptomatic cardiac arrhythmia * No history of myocardial infarction * No significant ventricular conduction abnormality by ECG or Holter monitoring, as evidenced by any of the following: * Prior myocardial infarction * Three or more premature ventricular contractions in a row * No history of pancreatitis * No history of recent gastrointestinal bleeding * Must have heme-negative stool at enrollment NOTE: \*Cytopenias due to direct lymphomatous involvement allowed NOTE: \*\*Elevated due to direct lymphomatous involvement allowed PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 3 weeks since prior chemotherapy * Recovered from prior chemotherapy (alopecia or anemia allowed) * More than 3 weeks since prior investigational drugs * No prophylactic antiemetics during course 1 * No other concurrent investigational drugs